PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.62
D/E ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.16. Howard Marks would check for debt covenant compliance and refinancing risks.
-1.57
Net cash position versus Drug Manufacturers - Specialty & Generic median net debt of 1.17. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
-6.54
Negative coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
3.37
Current ratio 1.25-1.5x Drug Manufacturers - Specialty & Generic median of 2.62. Philip Fisher would check if strong liquidity supports growth investments.
50.46%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 6.38%. Michael Burry would check for aggressive accounting and hidden risks.